4.0000
0.0000
(0.00%)
At close: January 30 at 9:15:03 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
903,029.0000
221,984.0000
209,711.0000
27,910.0000
12,450.0000
Cost of Revenue
27,448.0000
30,543.0000
21,998.0000
3,328.0000
1,966.0000
Gross Profit
875,581.0000
191,441.0000
187,713.0000
24,582.0000
10,484.0000
Operating Expense
1,201,113.0000
1,064,077.0000
1,037,523.0000
894,417.0000
674,425.0000
Operating Income
-325,532.0000
-872,636.0000
-849,810.0000
-869,835.0000
-663,941.0000
Net Non Operating Interest Income Expense
-41,684.0000
-63,648.0000
-43,058.0000
-9,625.0000
-1,037.0000
Pretax Income
-370,364.0000
-932,862.0000
-887,172.0000
-832,249.0000
-675,448.0000
Tax Provision
-9,827.0000
-7,150.0000
-4,248.0000
-49,825.0000
2,158.0000
Net Income Common Stockholders
-360,285.0000
-925,637.0000
-882,924.0000
-782,424.0000
-677,606.0000
Diluted NI Available to Com Stockholders
-360,285.0000
-925,637.0000
-882,924.0000
-782,424.0000
-677,606.0000
Basic EPS
-1.25
-3.28
-3.35
-3.07
-3.14
Diluted EPS
-1.26
-3.28
-3.35
-3.07
-3.14
Basic Average Shares
290,898.9170
282,299.2690
263,668.8270
254,615.3220
215,909.1500
Diluted Average Shares
293,035.0240
282,299.2690
263,668.8270
254,615.3220
215,909.1500
Total Expenses
1,228,561.0000
1,094,620.0000
1,059,521.0000
897,745.0000
676,391.0000
Net Income from Continuing & Discontinued Operation
-360,285.0000
-925,637.0000
-882,924.0000
-782,424.0000
-677,606.0000
Normalized Income
-359,608.4407
-927,746.9840
-894,602.3150
-839,459.4400
-674,797.2500
Interest Income
35,730.0000
32,409.0000
9,727.0000
7,106.0000
5,218.0000
Interest Expense
77,414.0000
96,057.0000
52,785.0000
16,731.0000
6,255.0000
Net Interest Income
-41,684.0000
-63,648.0000
-43,058.0000
-9,625.0000
-1,037.0000
EBIT
-292,950.0000
-836,805.0000
-834,387.0000
-815,518.0000
-669,193.0000
EBITDA
-292,950.0000
-743,610.0000
-771,472.0000
-787,192.0000
-641,771.0000
Reconciled Cost of Revenue
27,448.0000
30,543.0000
21,998.0000
3,328.0000
1,966.0000
Reconciled Depreciation
--
93,195.0000
62,915.0000
28,326.0000
27,422.0000
Net Income from Continuing Operation Net Minority Interest
-360,285.0000
-925,637.0000
-882,924.0000
-782,424.0000
-677,606.0000
Total Unusual Items Excluding Goodwill
-695.0000
2,127.0000
11,737.0000
60,676.0000
-3,745.0000
Total Unusual Items
-695.0000
2,127.0000
11,737.0000
60,676.0000
-3,745.0000
Normalized EBITDA
-292,255.0000
-745,737.0000
-783,209.0000
-847,868.0000
-638,026.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0001
0.0003
Tax Effect of Unusual Items
-18.4407
17.0160
58.6850
3,640.5600
-936.2500
12/31/2020 - 12/20/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PYPD PolyPid Ltd.
2.9899
+0.33%
TYRA Tyra Biosciences, Inc.
14.71
+0.41%
ANTX AN2 Therapeutics, Inc.
1.1700
-0.85%
AURA Aura Biosciences, Inc.
7.93
+0.13%
UPB Upstream Bio, Inc.
11.00
+7.32%
ALMS Alumis Inc.
6.72
+2.91%
MBX MBX Biosciences, Inc.
11.64
+13.34%
SLN Silence Therapeutics plc
5.25
+0.19%
LXEO Lexeo Therapeutics, Inc.
5.25
+0.77%
APGE Apogee Therapeutics, Inc.
42.50
+5.41%